RGEN stock holds steady as Repligen backs 2026 growth

Repligen Corporation (US7607591002) remains a data-driven stock story on 23 July 2026, with the company guiding to 2026 revenue growth and investors still watching the latest reported margin and cash metrics. The short-term market setup is shaped by the company’s own financial record and its listed status on Nasdaq.

2026 growth frame

Repligen told investors in its latest outlook that 2026 revenue growth is part of the current setup, while the company’s earlier reporting showed how quickly the business can scale. In 2025, Repligen reported revenue of $614.6 million, up 12.3% from $547.5 million in 2024, and adjusted earnings per share of $1.86 versus $1.60 a year earlier.

The same 2025 period also showed adjusted gross margin at 51.8%, giving the stock a clear profitability reference point. That margin level matters because it shows how much operating leverage Repligen can capture if demand stays firm.

Margin and cash matter

Repligen ended 2025 with cash, cash equivalents and marketable securities of $1.1 billion, a large liquidity cushion for a company its size. It also posted $83.4 million of operating cash flow in 2025, which gives investors a second line of evidence beyond revenue growth.

Those figures create a useful comparison with the prior year: operating cash flow improved from $67.2 million in 2024, while revenue advanced by $67.1 million year on year. For a stock trading off expectations rather than a single headline catalyst, the combination of growth, margin and liquidity is the core read-through.

Nasdaq listing context

Repligen stock trades on Nasdaq, and that listing keeps the shares in the same broad US biotech-tools conversation as other life-science suppliers. The market backdrop matters because the company’s results are judged against both growth and margin discipline, not revenue alone.

Product lens on chromatography

Repligen’s product mix is built around filtration, chromatography and fluid management tools used in bioprocessing, which is why the revenue base is tied to recurring industry demand rather than a single consumer cycle. That makes the company’s order and margin path more important than a one-time product launch.

Stock level context

Repligen stock is best read through its 2025 operating base until a fresh quote-driven move is visible in the tape. Revenue of $614.6 million, adjusted EPS of $1.86, and operating cash flow of $83.4 million form the clearest dated reference points for the shares as of 23 July 2026.